Quick Answer
Lexeo Therapeutics, Inc. reported Total Revenue of $654.0 thousand for fiscal year 2022.
Lexeo Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | $654.0K | — |
| Revenue (ASC 606) | — | — | — | $654.0K | — |
| Net Income | -$99.96M -1.7% |
-$98.33M -48.1% |
-$66.39M -12.0% |
-$59.28M | — |
| Diluted EPS | -$1.86 +39.8% |
-$3.09 +75.1% |
-$12.40 +65.9% |
-$36.36 | — |
| Total Assets | $268.69M +82.9% |
$146.94M +5.1% |
$139.81M +44.0% |
$97.08M | — |
| Cash and Equivalents | $63.00M +79.9% |
$35.01M -71.2% |
$121.47M +57.1% |
$77.33M -43.1% |
$135.86M |
| Stockholders Equity | $246.67M +111.1% |
$116.84M +2.9% |
$113.53M +200.5% |
-$112.95M -103.1% |
-$55.60M |
| R&D Expense | $63.80M -13.9% |
$74.09M +39.5% |
$53.13M +8.1% |
$49.16M | — |
| Operating Income | -$109.26M -3.3% |
-$105.77M -54.4% |
-$68.51M -13.2% |
-$60.51M | — |
| Shares Outstanding | 73.00M +120.7% |
33.07M +24.1% |
26.65M +1558.0% |
1.61M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $531.0K | — | — |
| Revenue (ASC 606) | September 30, 2022 | $531.0K | — | — |
| Net Income | September 30, 2025 | -$20.28M | +31.2% | +22.3% |
| Diluted EPS | September 30, 2025 | -$0.33 | +62.9% | +45.0% |
| Total Assets | September 30, 2025 | $143.84M | -17.3% | -18.3% |
| Cash and Equivalents | September 30, 2025 | $41.00M | -73.9% | +15.5% |
| Stockholders Equity | September 30, 2025 | $120.83M | -13.3% | -12.6% |
| R&D Expense | September 30, 2025 | $15.70M | -33.0% | +6.6% |
| Operating Income | September 30, 2025 | -$21.65M | +31.4% | +29.5% |
| Shares Outstanding | September 30, 2025 | 54.93M | +66.2% | +1.7% |
- Lexeo Therapeutics, Inc. reported Total Revenue of $654.0 thousand for fiscal year 2022.
- Lexeo Therapeutics, Inc. reported Revenue (ASC 606) of $654.0 thousand for fiscal year 2022.
- Lexeo Therapeutics, Inc. reported Net Income of -$99.96 million for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed a decrease of -1.7% in Net Income compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported Diluted EPS of $1.86 per share (loss) for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed an increase of +39.8% in Diluted EPS compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported Total Assets of $268.69 million for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed an increase of +82.9% in Total Assets compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported Cash and Equivalents of $63.00 million for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed an increase of +79.9% in Cash and Equivalents compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported Stockholders Equity of $246.67 million for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed an increase of +111.1% in Stockholders Equity compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported R&D Expense of $63.80 million for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed a decrease of -13.9% in R&D Expense compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported Operating Income of -$109.26 million for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed a decrease of -3.3% in Operating Income compared to the prior fiscal year.
- Lexeo Therapeutics, Inc. reported Shares Outstanding of 73.00 million shares for fiscal year 2025.
- Lexeo Therapeutics, Inc. showed an increase of +120.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: